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Background: We assessed the activity of ceftolozane/tazobactam against consecutive isolates collected in the
BSAC Bacteraemia Surveillance from 2011 to 2015 and against ‘problem’ isolates sent to the UK national refer-
ence laboratory from July 2015, when routine testing began.
Methods: Susceptibility testing was by BSAC agar dilution with resistance mechanisms identified by PCR and in-
terpretive reading.
Results:Data were reviewed for 6080 BSAC surveillance isolates and 5473 referred organisms. Ceftolozane/tazo-
bactam had good activity against unselected ESBL producers in the BSAC series, but activity was reduced against
ertapenem-resistant ESBL producers, which were numerous among reference submissions. AmpC-derepressed
Enterobacter spp. were widely resistant, but Escherichia coli with raised chromosomal AmpC frequently
remained susceptible, as did Klebsiella pneumoniae with acquired DHA-1-type AmpC. Carbapenemase-
producing Enterobacteriaceae were mostly resistant, except for ceftazidime-susceptible isolates with OXA-48-
like enzymes. Ceftolozane/tazobactam was active against 99.8% of the BSAC Pseudomonas aeruginosa isolates;
against referred P. aeruginosa it was active against 99.7% with moderately raised efflux, 94.7% with strongly
raised efflux and 96.6% with derepressed AmpC. Resistance in P. aeruginosa was largely confined to isolates with
metallo-b-lactamases (MBLs) or ESBLs. MICs for referred Burkholderia spp. and Stenotrophomonas maltophilia
were 2–4-fold lower than those of ceftazidime.
Conclusions: Ceftolozane/tazobactam is active against ESBL-producing Enterobacteriaceae; gains against other
problem Enterobacteriaceae groups were limited. Against P. aeruginosa it overcame the two most prevalent
mechanisms (up-regulated efflux and derepressed AmpC) and was active against 51.9% of isolates non-
susceptible to all other b-lactams, rising to 80.9% if ESBL and MBL producers were excluded.
Introduction
Ceftolozane/tazobactam is a cephalosporin/b-lactamase inhibitor
combination, recently licensed for complicated intra-abdominal
and urinary tract infections.1 EUCAST breakpoints, with a fixed
4 mg/L concentration of tazobactam, are susceptible 1 mg/L/re-
sistant .1 mg/L for Enterobacteriaceae and 4/>4 mg/L for
Pseudomonas aeruginosa. Tazobactam protects ceftolozane
against ESBLs, with the combination’s efficacy against producers
confirmed in the Phase III trials.1 Ceftolozane is also notably active
against P. aeruginosa, with MICs lower than ceftazidime—hitherto
the most active anti-pseudomonal b-lactam.2 This activity is re-
tained for many strains with derepressed AmpC or up-regulated
efflux,2 which are the major routes to resistance to established
penicillins and cephalosporins in the species.3
Here, we review the activity of ceftolozane/tazobactam against
two large, contrasting series of Gram-negative isolates. First, we
considered consecutive bloodstream isolates collected by the
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BSAC Bacteraemia Surveillance during 2011–15. Secondly, we re-
viewed isolates referred to PHE’s Antimicrobial Resistance and
Healthcare Associated Infections (AMRHAI) Reference Unit in the
first year that ceftolozane/tazobactam was tested; thereby provid-
ing a large snapshot of UK ‘problem’ organisms.
Materials and methods
BSAC surveillance
The BSAC Bacteraemia Surveillance has been described previously.4 Results
were reviewed from 2011, when testing of ceftolozane/tazobactam began,
to 2015; 38–40 UK and Irish laboratories contributed annually, submitting
up to seven consecutive bloodstream isolates each of Klebsiella,
Enterobacter and Pseudomonas spp. and up to 14 Escherichia coli.
Identifications were confirmed at AMRHAI by MALDI-TOF or API20E or
API20NE strips (bioMe´rieux, Marcy-l’Etoile, France). Among Pseudomonas
spp., only confirmed P. aeruginosa were considered; these comprised
95.1% of all Pseudomonas spp. collected. Susceptibility testing was by BSAC
agar dilution.5 Enterobacteriaceae with cefotaxime or ceftazidime MICs
1 mg/L were further characterized by: (i) comparing cefepime, cefotaxime
and ceftazidime MICs with and without 4 mg/L clavulanate to identify ESBL
producers (with 8-fold potentiation of 1 cephalosporin); (ii) comparing
cefotaxime MICs with and without 100 mg/L cloxacillin to identify AmpC
producers (with 4-fold potentiation, no cephalosporin/clavulanate po-
tentiation, and 8-fold higher MICs of cefotaxime and ceftazidime than
cefepime); and (iii) by PCR for blaCTX-M and plasmid AmpC enzymes.
Enterobacteriaceae with reduced carbapenem susceptibility were screened
for carbapenemase genes by PCR, as were P. aeruginosa that were both (i)
broadly resistant to b-lactams and (ii) positive for imipenem/EDTA synergy.
Reference submissions
MICs, determined by BSAC agar dilution,5 were reviewed for all non-
fastidious Gram-negative bacteria referred to PHE’s AMRHAI Reference Unit
over 1 year from July 2015, when routine testing of ceftolozane/tazobac-
tam began. Around 90% of submission are from diagnostic laboratories in
England, 9% from elsewhere in the UK and 1% from overseas, principally
Ireland. We excluded isolates tested for internal and external quality assur-
ance and repeat/multiple tests on the same isolate from the same submis-
sion. Testing employed a wide panel of antibiotics. To predict b-lactamase
types, MICs of cefotaxime/clavulanate 2 mg/L, cefotaxime/cloxacillin
100 mg/L, ceftazidime/clavulanate 2 mg/L, ceftazidime/avibactam 2 mg/L,
cefepime/clavulanate 2 mg/L and imipenem/EDTA 320 mg/L were com-
pared with those of the sameb-lactams alone.
Genes for KPC, VIM, NDM and OXA-48-like carbapenemases were
sought by multiplex PCR. Enterobacteriaceae resistant to meropenem and
imipenem but lacking genes for these common carbapenemases were sub-
jected to further multiplex PCRs, seeking (i) blaIMP, blaVIM, blaSPM, blaGIM,
blaSIM and blaNDM and (ii) blaFRI, blaGES, blaIMI and blaSME. Metallo-
carbapenemase genes were sought in P. aeruginosa isolates showing 8-
fold or greater imipenem/EDTA synergy together with broad resistance to
penicillins and cephalosporins. blaVEB and blaPER genes were sought by PCR
in most P. aeruginosa isolates with ceftazidime MICs.256 mg/L and cef-
tazidime/clavulanate MICs 32 mg/L. Referred Acinetobacter spp. isolates
were screened for blaOXA-51-like to identify A. baumannii where this gene is
universal and chromosomal.
Categorization of isolates
Detection of a b-lactamase gene was considered ‘definitive’ identification
of a mechanism. Carbapenemase-negative isolates were categorized by in-
house mathematical algorithms employing the principles of interpretive
reading of phenotypes.6 Two levels of match were allowed: ‘hard’, where
the phenotype was a perfect match; and ‘soft’, where the phenotype was
less perfectly matched, but the mechanism remained the most likely.
For example, to meet hard-match criteria for highly raised (putatively
MexAB-OprM-mediated) efflux, a P. aeruginosa isolate required a carbenicil-
lin MIC .512 mg/L with carbencillin:cefotaxime:piperacillin:ceftazidime
MIC ratios in the ranges 1:0.25–1:0.03–0.12:0.015–0.06 (note these are ratios,
not actual MICs, and are predicated on the fact that up-regulated MexAB-
OprM raises MICs of these agents in rough proportion);4 to meet soft-match -
criteria the strain needed a carbenicillin MIC .512 mg/L and
carbenicillin:cefotaxime:piperacillin:ceftazidime MIC ratios in the ranges
1:0.12–2:0.015–0.25:0.008–0.12. Some isolates did not match any of the
phenotypes considered and were left as ‘unassigned’, then categorized ac-
cording to their level of resistance to reference agents, principally ceftazidime.
Results
BSAC Bacteraemia Surveillance isolates
The BSAC collection provided a random and geographically diverse
sample of bloodstream isolates. Because no temporal trend
was seen for ceftolozane/tazobactam (not shown), data for
2011 to 2015 were pooled (Table 1). Using EUCAST’s 1!4 mg/L
Enterobacteriaceae breakpoint, susceptibility rates to ceftolozane/
tazobactam were 91.5% for Enterobacter spp., 97.6% for Klebsiella
spp. and 99.7% for E. coli, exceeding those for all other b-lactams
tested except carbapenems. In the case of P. aeruginosa, 99.8% of
isolates (1097/1099) were susceptible at EUCAST’s 4!4 mg/L
breakpoint, versus 97.9% for gentamicin, 97.6% for ceftazidime,
95.5% for piperacillin/tazobactam, 91.7% for meropenem (not
tested in 2012 and 2013), 92.5% for imipenem (not tested in
2014) and 90.4% for ciprofloxacin.
Almost all ESBL- and AmpC-producing E. coli (97.9% and
96.6%, respectively) were susceptible to ceftolozane/tazobactam
1!4 mg/L, as were 93.7% of Klebsiella oxytoca hyperproducing K1
b-lactamase. Susceptibility rates for ESBL-producing Klebsiella and
Enterobacter were lower, at 84%–85%. Around half the ceftolo-
zane/tazobactam resistance among ESBL-producing Klebsiella
was low level, with MICs of 2!4 mg/L; but other isolates were sub-
stantially resistant, with MICs up to .256 mg/L. High MICs were
not associated with particular ESBL types: 9/13 (69.2%) ESBL-
producing isolates with MICs.8 mg/L had CTX-M group 1 enzymes,
as did 85/140 (60.7%) with MICs 1 mg/L. It is possible that the
more resistant isolates had larger amounts of ESBL, a different CTX-
M variant, or multiple b-lactamases. Half of the AmpC-
hyperproducing Enterobacter spp. were resistant; significantly, these
ceftolozane/tazobactam-resistant organisms also were much more
resistant to cefotaxime and ceftazidime (geometric mean MICs
76.8 and 69.8 mg/L respectively) than were ceftolozane/
tazobactam-susceptible AmpC enterobacters (geometric mean
cefotaxime and ceftazidime MICs 6.5 and 5.0 mg/L, respectively). It
is likely that this variation reflected the amount of AmpC enzyme.
Just 11/4981 (0.2%) BSAC E. coli, Klebsiella and Enterobacter
spp. isolates had carbapenemases, 2 with KPC, 3 with VIM and 6
with OXA-48-like enzymes. Three of the six with OXA-48-like en-
zymes were susceptible to ceftazidime at breakpoint (1 mg/L);
these also were susceptible to ceftolozane/tazobactam 1!4 mg/L.
The remaining three OXA-48-like isolates, which were resistant to
ceftazidime (MICs 16–128 mg/L), also were resistant to ceftolo-
zane/tazobactam, as were all the isolates with KPC and VIM
enzymes.
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One of the two ceftolozane/tazobactam-resistant P. aeruginosa,
with an MIC of 32!4 mg/L, had a VIM carbapenemase;
mechanisms remain uncertain in the other, with an MIC of
8!4 mg/L.
Isolates referred to PHE
The isolates examined in ceftolozane/tazobactam’s first year of
testing comprised 3249 Enterobacteriaceae, 1414 P. aeruginosa
and 810 other non-fermenters, including 419 Acinetobacter spp.
They lack a denominator and are referred for numerous reasons.
There is a considerable bias towards submitting isolates suspected
of carbapenem resistance, but some have suspected colistin, ami-
noglycoside or tigecycline resistance; a few are referred owing to
anomalous susceptibility, e.g. to ampicillin in P. aeruginosa. The
overall performance data shown in Table 2 should be considered
with these biases in mind. Nevertheless two points are striking:
first, that ceftolozane/tazobactam was more widely active against
these ‘problem’ P. aeruginosa than any other b-lactam, whereas,
secondly, gains against problem Enterobacteriaceae were modest,
with carbapenems remaining more active.
Enterobacteriaceae by inferred or proven mechanism
Table 3 shows the MIC distributions of ceftolozane/tazobactam for
referred Enterobacteriaceae by species and resistance type.
Because there was little difference in their distributions, MICs are
pooled for the hard- and soft-matched groups.
At its 1!4 mg/L breakpoint, ceftolozane/tazobactam was active
against 41.7% of the ESBL producers, rising to 53.0% for E. coli and
falling to 26.3% for Klebsiella pneumoniae. It was active also
against 26.2% of AmpC hyperproducers, rising to 50.8% for E. coli
and 88.9% for Morganella morganii, but falling to 18.4% for
Enterobacter spp. The high susceptibility rate for AmpC-
derepressed M. morganii reflects the vulnerability of Morganella
AmpC to tazobactam,7 whilst frequent susceptibility in E. coli was
associated with cefotaxime and ceftazidime MICs of 2–4 mg/L, a
phenotype usually reflecting small elevations of chromosomal
AmpC via promoter mutations.8 Frequent resistance among the
AmpC Enterobacter spp. is in keeping with the fact that 554/649
(85.4%) of these referrals had high-level cefotaxime resistance
(MIC 32 mg/L), as typically associated with total derepression of
chromosomal enzyme. Klebsiella spp. have no chromosomal
ampC, meaning AmpC phenotypes in this genus reflect acquired,
Table 1. MIC distributions of ceftolozane/tazobactam for E. coli, Klebsiella spp., Enterobacter spp. and P. aeruginosa in the BSAC Bacteraemia
Surveillance Programme, 2011–15 inclusive
No. of isolates with indicated ceftolozane/tazobactam MIC (mg/L)
Organism 0.03 0.06 0.12 0.25 0.5 1 2 4 8 16 32 64 128 256 .256 Total %Sa
All
E. coli 2 67 1710 775 94 20 5 3 2676 99.7
Enterobacter spp. 2 18 160 568 114 61 27 26 22 8 2 1 1009 91.5
Klebsiella spp. 12 338 662 192 61 14 2 2 1 1 4 2 4 1 1296 97.6
P. aeruginosa 7 242 756 82 6 4 1 1 1099 99.8
ESBL (all)
E. coli 1 42 151 66 15 4 2 281 97.9
Enterobacter spp. 3 17 14 6 4 1 1 1 47 85.1
Klebsiella spp. 4 11 57 28 9 1 1 1 3 1 3 119 84.0
CTX-M group 1 ESBLsb
E. coli 29 133 54 12 3 2 233 97.9
Enterobacter spp. 3 7 4 2 16 87.5
Klebsiella spp. 3 7 47 14 2 1 1 3 1 3 82 86.6
AmpC
E. coli 6 16 5 1 1 29 96.6
Enterobacter spp. 3 14 20 35 20 24 20 6 1 1 144 50.0
ESBL! AmpC
Enterobacter 7 4 4 2 1 1 1 20 75
Klebsiella spp. 1 1 1/1
Others
K1 K. oxytoca 1 8 9 9 2 29 93.7
KPC Klebsiella 1 1 2 0/2
VIM Klebsiella 1 1 1 3 0/3
OXA-48 Enterobacteriaceae 3 1 2 6 3/6
aS, susceptible. Based on a breakpoint of 1!4 mg/L for Enterobacteriaceae and 4!4 mg/L for P. aeruginosa; percentage susceptibility is cited if.10
isolates, otherwise the proportion of isolates found susceptible is shown.
bExcluding isolates also found to have carbapenemase and/or AmpC activity.
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plasmid-mediated enzymes: a 51.0% susceptibility rate accords
with the observation that many examined by PCR (24/26) had
blaDHA, a chromosomal ‘escape’ from M. morganii encoding a
tazobactam-inhibited variant.9 Close relationships existed be-
tween ceftolozane/tazobactam MIC and ertapenem MICs for ESBL
and AmpC producers, with the percentage of isolates susceptible
to ceftolozane/tazobactam falling as ertapenem MIC increased
(Figure 1). Previous experience indicates that raised ertapenem
MICs for such carbapenemase-negative isolates mostly reflect
porin loss.10,11
As with the BSAC series, ceftolozane/tazobactam was widely ac-
tive (6/8 isolates susceptible) against K. oxytoca with high-level K1
enzyme, whereas activity against carbapenemase producers was
very limited. All metallo-b-lactamase (MBL)-producing Enterobac-
teriaceae were resistant, as were almost all with KPC and GES-5 en-
zymes. On the other hand, 9/12 with rare class A carbapenemases
(i.e. IMI, SME or FRI types) remained susceptible, probably because
these enzymes are poor cephalosporinases. OXA-48-like carbape-
nemases are poor cephalosporinases too, especially against cef-
tazidime.12 On this basis, we categorized the OXA-48 producers as
either ceftazidime-susceptible/intermediate (MIC4 mg/L, EUCAST
criteria) or ceftazidime-resistant (MIC .4 mg/L), inferring that the
latter group had additional mechanisms such as ESBLs. Despite the
presence of tazobactam (which should inhibit ESBLs), ceftolozane/
tazobactam MICs closely tracked those of unprotected ceftazidime:
thus, 81.9% of the ceftazidime-susceptible/intermediate isolates
were susceptible to ceftolozane/tazobactam at 1!4 mg/L, versus
8.1% of ceftazidime-resistant isolates.
Ceftolozane/tazobactam was active against around 80% of
Enterobacteriaceae isolates inferred to have reduced permeability
without ESBL, AmpC or carbapenemase activity—a group
also widely susceptible (MIC1 mg/L, EUCAST) to cefotaxime
(59.6%), ceftazidime (48.3%) and cefepime (56.2%). Ceftolozane/
tazobactam also, unsurprisingly, had near-universal activity
against cephalosporin-susceptible WTs. For isolates (mostly
K. pneumoniae) with unassigned mechanisms, ceftolozane/tazo-
bactam MICs tracked those of unprotected ceftazidime, with 86.8%
susceptibility for isolates inhibited by ceftazidime at 4 mg/L, 5.8%
for those with ceftazidime MICs of 8–32 mg/L and universal resist-
ance among those with ceftazidime MICs64 mg/L. It should, how-
ever, be stressed that these groups are diverse, and include several
phenotypes under active investigation.
P. aeruginosa
The two largest groups of referred P. aeruginosa were those
inferred to have increased efflux or derepressed AmpC. The
increased efflux group was subcategorized into those with car-
benicillin MICs of 256–512 mg/L and those with carbenicillin MICs
.512 mg/L (Table 4). MICs of ceftolozane/tazobactam increased
in tandem with those of carbenicillin, piperacillin and ceftazidime
for these isolates (Table 4); nevertheless, even among efflux-type
isolates with carbenicillin MICs .512 mg/L, 94.7% remained sus-
ceptible to ceftolozane/tazobactam 4!4 mg/L, versus 27.6% for
ceftazidime and 5.9% for piperacillin/tazobactam. Among efflux-
type isolates with carbenicillin MICs 256–512 mg/L, all but one
Table 2. Overall susceptibilities of Enterobacteriaceae and P. aeruginosa referred to AMRHAI
Enterobacteriaceae (n"3249) P. aeruginosa (n"1414)
BP (mg/L) no. S %S BP (mg/L) no. S %S
Colistin S2 2951 90.8 S2 1351 95.5
S4 1369 96.8
Amikacin S8 2729 84.0 S8 1033 73.1
Tigecycline S1 2449 75.4 — — —
Imipenem S2 2365 72.8 S4 235 16.6
Gentamicin S2 2062 63.5 S4 991 70.1
Meropenem S2 2300 70.8 S2 149 10.5
S4 245 17.3
Tobramycin S2 1748 53.8 S4 1031 72.9
Ciprofloxacin S0.5 1465 45.1 S0.5 535 37.8
Ceftolozane/tazobactam S1!4 1048 32.3 S4!4 1193 84.4
Cefepime S1 947 29.1 S8 744 52.6
Temocillin S8 880 27.1 — — —
Ertapenem S0.5 731 22.5 — — —
Aztreonam S1 678 20.9 — — —
Piperacillin/tazobactam S8!4 531 16.3 S16!4 661 46.7
Ceftazidime S1 505 15.5 S8 802 56.7
Cefotaxime S1 432 13.3 — — —
Amoxicillin/clavulanate S8 118 3.6 — — —
Ampicillin S8 18 0.6 — — —
Carbenicillin — — — S128 555 39.3
BP, breakpoint; no. S, number susceptible; %S, percentage susceptible.
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Table 3. MIC distributions of ceftolozane/tazobactam, by resistance group and species group, for Enterobacteriaceae referred to AMRHAI, July 2015–
July 2016
Matching to mechanism No. of isolates with indicated MIC (mg/L)
molecular harda softa total 0.25 0.5 1 2 4 8 16 .16 void %S at 1!4 mg/L BP
ESBL producers
Citrobacter spp. 2 2 1 1 50.0
E. coli 337 25 362 100 57 35 38 21 17 32 61 1 53.0
Enterobacter spp. 45 4 49 6 4 10 7 4 6 6 6 40.8
K. oxytoca 3 3 1 1 1 33.3
K. pneumoniae 229 26 255 17 27 23 39 23 24 28 74 26.3
rare fermenters 2 2 2 0.0
Serratia spp. 1 1 1 0.0
all 616 58 674 123 89 69 87 49 48 66 142 1 41.7
AmpC hyperproducers
Citrobacter spp. 39 7 46 3 3 4 6 8 8 7 7 21.7
E. coli 101 19 120 35 15 11 11 8 11 7 22 50.8
Enterobacter spp. 625 24 649 13 53 53 95 131 115 125 63 1 18.4
Hafnia alvei 11 1 12 1 1 2 8 8.3
K. pneumoniae 39 10 49 9 6 10 3 6 3 12 51.0
M. morganii 7 2 9 3 3 2 1 88.9
Providencia spp. 1 1 1 0.0
rare fermenters 1 1 1 0.0
Serratia spp. 30 4 34 1 16 10 4 1 1 1 50.0
all 854 67 921 63 81 97 123 156 141 145 114 1 26.2
Isolates with both ESBL! AmpC activity
Citrobacter spp. 1 1 1 1 0.0
E. coli 28 14 42 2 1 1 4 5 29 42 7.1
Enterobacter spp. 18 2 20 1 1 4 3 9 2 20 10.0
K. pneumoniae 6 2 8 1 1 1 5 8 12.5
all 53 18 71 8.5
K1 hyperproducers
K. oxytoca 8 8 3 3 1 1 75.0
KPC producers
Citrobacter spp. 4 4 2 2 0.0
E. coli 36 36 1 2 9 14 7 2 1 8.3
Enterobacter spp. 28 28 1 3 5 7 8 4 3.6
K. oxytoca 4 4 1 1 2 25
K. pneumoniae 138 138 1 1 4 44 29 33 26 1.4
rare fermenters 2 2 2 0.0
Serratia spp. 4 4 3 1 0.0
all 216 216 2 1 4 17 63 47 50 32 3.2
GES carbapenemases
E. coli 4 4 1 3 0.0
Enterobacter spp. 1 1 1 0.0
K. oxytoca 15 15 11 4 0.0
K. pneumoniae 3 3 1 1 1 0.0
rare fermenters 1 1 1 0.0
Serratia spp. 1 1 1 0.0
all 25 25 2 2 12 9 0.0
Other class A carbapenemases
Enterobacter spp. 8 8 3 3 1 1 87.5
Serratia spp. 4 4 1 1 2 50.0
all 12 12 3 4 2 2 1 75.0
Continued
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Table 3. Continued
Matching to mechanism No. of isolates with indicated MIC (mg/L)
molecular harda softa total 0.25 0.5 1 2 4 8 16 .16 void %S at 1!4 mg/L BP
MBL producers
Citrobacter spp. 13 13 1 12 0.0
E. coli 95 95 95 0.0
Enterobacter spp. 29 29 29 0.0
K. oxytoca 3 3 3 0.0
K. pneumoniae 169 169 169 0.0
M. morganii 2 2 2 0.0
Providencia spp. 4 4 4 0.0
Serratia spp. 1 1 1 0.0
all 316 316 1 315 0.0
Isolates with both NDM! OXA-48 carbapenemases
E. coli 4 4 4 0.0
K. pneumoniae 28 28 28 0.0
all 32 32 32 0.0
OXA-48 producers ceftazidime 4 mg/L
Citrobacter spp. 3 3 1 2 100
E. coli 74 74 24 33 8 7 1 1 87.8
Enterobacter spp. 22 22 1 6 8 7 68. 2
K. oxytoca 3 3 1 2 100
K. pneumoniae 50 50 2 16 20 9 3 76
rare fermenters 1 1 1 100
Serratia spp. 2 2 2 100
all 155 155 28 57 42 23 4 1 81.9
OXA-48 producers ceftazidime .4 mg/L
Citrobacter spp. 10 10 4 6 0.0
E. coli 59 59 4 6 3 9 13 5 19 17.0
Enterobacter spp. 23 23 4 3 4 3 5 4 17.4
K. oxytoca 4 4 1 2 1 0.0
K. pneumoniae 100 100 1 1 3 5 10 8 72 2
Serratia spp. 2 2 2 0.0
all 198 198 1 5 10 9 18 27 24 104 8.1
Impermeability
E. coli 36 36 6 14 8 4 3 1 6 77.8
K. oxytoca 1 1 1 0.0
K. pneumoniae 51 51 2 11 28 8 2 2 80.4
all 88 88 8 25 36 13 5 1 78.4
WT, cephalosporin susceptible
Citrobacter spp. 2 2 1 1 100
E. coli 35 35 34 1 100
Enterobacter spp. 47 47 30 14 2 1 97.9
K. oxytoca 2 2 1 1 100
K. pneumoniae 18 18 17 1 100
M. morganii 14 14 12 1 1 92.9
Providencia spp. 2 2 1 1 100
rare fermenters 6 6 4 2 100
Serratia spp. 19 19 4 7 6 1 1 89.5
all 145 145 104 26 11 3 1 97.2
Unassigned, ceftazidime MIC4 mg/L
Citrobacter spp. 2 1 1 50
E. coli 75 48 13 14 100
Enterobacter spp. 12 1 1 8 2 83.3
K. oxytoca 9 1 2 5 1 11.1
Continued
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(99.7%) were susceptible to ceftolozane/tazobactam versus
65.3% for ceftazidime and 39.4% for piperacillin/tazobactam.
Ceftolozane/tazobactam retained activity against 96.6% of
P. aeruginosa inferred to have derepressed AmpC, whereas
ceftazidime was active against only 20.8%, rising to 94.5% for cef-
tazidime/avibactam. Carbenicillin, which has good stability to
pseudomonal AmpC,13 remained active against 84.6% of AmpC-
derepressed isolates at its 128 mg/L breakpoint. Isolates with ‘WT’
Table 3. Continued
Matching to mechanism No. of isolates with indicated MIC (mg/L)
molecular harda softa total 0.25 0.5 1 2 4 8 16 .16 void %S at 1!4 mg/L BP
K. pneumoniae 61 17 17 17 8 1 1 83.6
Providencia spp. 2 2 100
rare fermenters 1 1 100
Serratia spp. 7 4 2 1 57.1
all 167 67 34 44 15 7 2 86.8
Unassigned, ceftazidime MIC 8-32 mg/L
Citrobacter spp. 1 1 0.0
E. coli 10 1 1 1 1 2 4 20
Enterobacter spp. 5 1 1 1 2 20
K. oxytoca 3 1 2 0.0
K. pneumoniae 49 1 13 24 8 3 2.0
rare fermenters 1 1 0.0
all 69 1 1 2 15 27 9 8 6 5.8
Unassigned, ceftazidime MIC64 mg/L
Citrobacter spp. 2 1 1 0.0
E. coli 80 1 2 1 36 40 0.0
Enterobacter spp. 16 1 7 8 0.0
K. oxytoca 2 1 1 0.0
K. pneumoniae 204 9 7 86 102 0.0
all 304 1 12 8 131 152 0.0
BP, breakpoint; %S, percentage susceptible.
aHard-matched, isolate’s antibiogram conforms precisely to expected phenotype for the mechanism; soft-matched, isolate’s antibiogram best
matches the phenotype expected for the mechanism, but with minor discrepancies.
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carbenicillin MICs of 32–128 mg/L and without additional mechan-
isms affecting piperacillin/tazobactam or ceftazidime were split
according to imipenem non-susceptibility (MIC.4 mg/L), which
was taken as a marker of OprD loss; ceftolozane/tazobactam MICs
were independent of this trait.
In contrast to this good activity against isolates with elevated
efflux, derepressed AmpC or loss of OprD, resistance to ceftolo-
zane/tazobactam was near universal (96.8%–100%) among
P. aeruginosa with MBLs or VEB ESBLs. Isolates with these enzymes
also were broadly resistant to other penicillins and cephalosporins,
with resistance rates .95%, though 72% of MBL producers re-
mained intermediately susceptible to aztreonam according to
EUCAST criteria, with MICs of 2–16 mg/L. Ceftolozane/tazobactam
4!4 mg/L was active against 16/19 GES carbapenemase-positive
isolates, compared with 74% for ceftazidime 8 mg/L; however, 14
of these 19 were from a single outbreak, and the results may not
be generalizable. Aside from MBL and ESBL producers, the only
P. aeruginosa groups where ceftolozane/tazobactam resistance
was frequent were the unassigned categories with ceftazidime
MICs of 16–128 and256 mg/L. Ceftolozane/tazobactam MICs for
these isolates mostly were 8–16 mg/L, thus slightly lower than for
MBL and ESBL producers.
Two wider associations were seen. First, across all 1414
P. aeruginosa, there was broad correlation between the MICs of
ceftolozane/tazobactam and ceftazidime, with ceftolozane/tazo-
bactam MICs 2–8-fold lower except for isolates with MBLs or
ESBLs. Secondly, (Table 5) among 422 referred P. aeruginosa that
were non-susceptible to all established b-lactams (i.e. carbenicillin
MIC.128 mg/L, piperacillin/tazobactam.16!4 mg/L, ceftazidime
.8 mg/L, imipenem .4 mg/L and meropenem .4 mg/L), 51.9%
were susceptible to ceftolozane/tazobactam 4!4 mg/L, rising to
80.9% among the 267 lacking ESBLs, MBLs or GES enzymes.
Other non-fermenters
MIC distributions of ceftolozane/tazobactam for other non-
fermenters besides P. aeruginosa are shown in Table 4. The
A. baumannii submissions had a major bias towards carbapenem-
resistant isolates, with 303/355 non-susceptible to imipenem at its
2 mg/L breakpoint, mostly (.95%) owing to OXA carbapenemases
(not shown). Other species tend to be submitted owing to multire-
sistance, with many of the isolates from cystic fibrosis patients.
There are no ceftolozane/tazobactam breakpoints for
non-fermenters besides P. aeruginosa but a few general points can
be made. First, MICs for A. baumannii, Elizabethkingia spp. and
Pandoraea spp. were mostly above the P. aeruginosa breakpoint
of 4!4 mg/L, whereas MICs for non-baumannii Acinetobacter,
Burkholderia spp., Chryseobacterium spp., non-aeruginosa
Pseudomonas and Stenotrophomonas maltophilia were mostly
at or below this breakpoint. Secondly, 29/32 imipenem-susceptible
A. baumannii were susceptible to ceftolozane/tazobactam
4!4 mg/L versus only 44/303 imipenem-non-susceptible isolates.
Thirdly, the MICs of ceftolozane/tazobactam for S. maltophilia and
Burkholderia spp. correlated with those of ceftazidime, but were 2–
4-fold lower (Figure 2).
Discussion
Ceftolozane/tazobactam combines a new oxyimino-cephalosporin
with an established b-lactamase inhibitor. It is licensed for compli-
cated intra-abdominal and urinary tract infections, with efficacy
including ESBL-producing Enterobacteriaceae up to the 1!4 mg/L
breakpoint.1,14 Activity against P. aeruginosa is striking, but this spe-
cies was poorly represented in the licensing trials. We reviewed the
combination’s activity against: (i) consecutive bloodstream isolates
collected in the BSAC Bacteraemia Surveillance; and (ii) ‘problem’
Gram-negative bacteria submitted to AMRHAI. The latter lack a de-
nominator but provide a snapshot of organisms causing resistance
concerns in the UK. For both collections we categorized isolates
based on molecular data and interpretive reading.
The BSAC Bacteraemia Surveillance showed ceftolozane/tazo-
bactam to be active against 91.5%–99.7% of the major
Enterobacteriaceae species. Activity included 97.9% of ESBL E. coli,
but only 84%–85% of ESBL-producing Klebsiella and Enterobacter
spp. and 50% of AmpC-derepressed Enterobacter. The latter result
is in keeping with tazobactam being a poor inhibitor of
Enterobacter AmpC7 and ceftolozane being a substrate; high re-
sistance rates were likewise seen for referred AmpC-derepressed
Enterobacter (Table 3), and have been observed previously.15 The
15%–16% resistance rates for ESBL-producing Enterobacter and
Klebsiella in the BSAC Bacteraemia Surveillance are more surpris-
ing, since ESBLs are inhibited by tazobactam. About half this resist-
ance was borderline, with MICs of 2 mg/L, but MICs for the
remainder ranged up to 256 mg/L, with resistance not obviously
associated with ESBL type. Plausible explanations are that some
ESBL-producing Klebsiella and Enterobacter had secondary b-lac-
tamases or permeability lesions. Farrell et al.16 previously reported
12.1% ceftolozane/tazobactam resistance in ‘ESBL phenotype’
Table 5. Activity of ceftolozane/tazobactam against P. aeruginosa non-susceptible to all other anti-pseudomonal b-lactams
No. of isolates with indicated ceftolozane/tazobactam MIC (mg/L)
0.25 0.5 1 2 4 8 16 .16 Total %S
All 0 20 90 72 37 23 15 165 422 51.9
Excluding carbapenemase and known ESBL producers 0 20 90 71 35 21 12 18 267 80.9
%S, percentage susceptible.
Non-susceptibility to other b-lactams defined as carbenicillin MIC .128 mg/L, ceftazidime MIC .8 mg/L, piperacillin/tazobactam MIC .16 mg/L and
imipenem and meropenem MICs .4 mg/L, based on EUCAST breakpoints.
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E. coli and 69.6% resistance in ‘ESBL phenotype’ K. pneumoniae
from 41 medical centres in Europe, Turkey and Israel; these high
resistance rates seem unrepresentative of the generality of UK and
Irish ESBL producers and closer to results for referred problem iso-
lates (Table 3). They may reflect (i) larger proportions of ESBL pro-
ducers with secondary mechanisms in the countries surveyed, or
(ii) inclusion of strains with KPC enzymes, which can give a false
‘ESBL phenotype’ in terms of cephalosporin/clavulanate synergy.
Frequent resistance to ertapenem among referred ESBL and
AmpC producers is probably due to impermeability, and, among
these isolates, ceftolozane/tazobactam resistance was common
(Figure 1).
Unlike the BSAC collections, the AMRHAI referrals provided nu-
merous carbapenemase-producing Enterobacteriaceae, most of
which proved resistant to ceftolozane/tazobactam. This is unsur-
prising for MBL and KPC producers as (i) MBLs are not inhibited by
tazobactam and (ii) KPC enzymes hydrolyse penicillanic acid sul-
phones, mitigating inhibition.17 Better activity might be expected
against isolates with OXA-48-like enzymes, which are poorly active
against oxyimino-cephalosporins,12 with any cephalosporin resist-
ance arising from secondary mechanisms, principally ESBLs, which
should be inhibited by tazobactam. Yet, in reality, ceftolozane/
tazobactam susceptibility was largely restricted to those OXA-48-
like isolates that were susceptible or intermediate to unprotected
ceftazidime (MIC 4 mg/L) and therefore are inferred to lack sec-
ondary b-lactamases. Similar behaviour (not shown) was seen for
ceftazidime/clavulanate. Plausible explanations, deserving investi-
gation, are: (i) many resistant isolates additionally had permeabil-
ity lesions or multiple b-lactamases, thus overwhelming the
tazobactam; or (ii) OXA-48-like enzymes inactivate tazobactam
and clavulanate.
In contrast to this mixed performance against Enterobacteria-
ceae, ceftolozane/tazobactam was the most active b-lactam
against both series of P. aeruginosa isolates. For the BSAC isolates
its modal MIC was 4-fold lower than for ceftazidime and the
proportion non-susceptible was only 0.2%. More strikingly, ceftolo-
zane/tazobactam was active, at breakpoint, against 99.7% and
94.7% of referred isolates with moderately and strongly increased
efflux and against 96.6% with derepressed AmpC. These are the
most common resistance mechanisms in P. aeruginosa in the
UK18,19 and Western Europe,20–22 though MBLs and ESBLs, which
ceftolozane/tazobactam did not overcome, are more prevalent in
Russia, Eastern Europe and the Middle East.23–25 Ceftolozane does
not entirely escape efflux and AmpC, and its MICs are slightly
raised, nevertheless it is less compromised than other cephalo-
sporins and penicillins, and seems less prone to select for these
traits.26
High-level ceftolozane/tazobactam resistance (MIC .16 mg/L)
in P. aeruginosawas largely confined to isolates with MBLs or ESBLs,
and these associations were so strong that AMRHAI now uses a cef-
tolozane/tazobactam MIC .16 mg/L as a predictor of these en-
zymes for the species. The lack of activity against ESBL-producing P.
aeruginosa may seem surprising, since ESBL-producing
Enterobacteriaceae were widely susceptible, but we note: (i) the
predominant VEB ESBLs may be less susceptible to tazobactam
than the CTX-M, TEM and SHV enzymes of Enterobacteriaceae; and
(ii) tazobactam may be a poor permeant, or good efflux substrate,
for P. aeruginosa. Piperacillin/tazobactam by analogy is poorly ac-
tive against P. aeruginosawith acquired penicillinases.3
Ceftolozane/tazobactam offered no gain compared with earlier
cephalosporins against Acinetobacter spp. or Elizabethkingia spp.,
but was more active than ceftazidime against Burkholderia spp.
and S. maltophilia. b-Lactams remain controversial in infections
due to these species, with medium-dependent MICs27 and no
EUCAST breakpoints. Nevertheless they are often the next-most-
active option after co-trimoxazole in vitro, and may be considered
in sulphonamide-intolerant patients or those with co-trimoxazole-
resistant strains. Ceftazidime, meropenem and temocillin have the
No. of isolates with indicated MIC of ceftolozane/tazobactam (mg/L)  
Ceftazidime MIC (mg/L) ≤0.25 0.5 1 2 4 8 16 >16
0.25 2
40.5
16151 4
241222 6 3
5424 3 1 1
3738 1
8316 1 1
332 3 
664
4128
5256
2>256
Total: S. maltophilia (n=78) 9 16 19 10 3 5 2 14
Total: Burkholderia spp. (n=76) 14 14 16 8 9 5 2 8
Figure 2. MICs of ceftolozane/tazobactam in relation to those of ceftazidime for S. maltophilia and Burkholderia spp., pooled. Grey squares indicate
the line of equivalence, numbers below this line indicate that ceftolozane/tazobactam is more active than ceftazidime.
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lowest MICs among b-lactams for Burkholderia spp.,28 with ticarcil-
lin/clavulanate and ceftazidime the most active against
S. maltophilia.29 It now seems appropriate to add ceftolozane/
tazobactam to this list. Activity against S. maltophilia may reflect
tazobactam inhibiting the L-2 cephalosporinase, and this possibil-
ity deserves exploration.
In countries with conservative antimicrobial usage, such as the
UK, new agents enter use as microbiologically directed treatments
of problem infections, not as the empirical therapy modelled by
Phase III trials. P. aeruginosa is the likely major target for ceftolo-
zane/tazobactam, since b-lactams are core to anti-pseudomonal
regimens and the combination inhibited many isolates resistant to
all other b-lactams (Table 5). Results of a high-dosage ventilator-
associated pneumonia trial, where P. aeruginosa is likely to be a
frequent pathogen, are awaited with interest. In the meantime
there is a growing catalogue of case reports of success in chronic
and acute P. aeruginosa infections.30–34 These data are encourag-
ing, although reports of resistance associated with AmpC se-
quence variants are a concern.26,35
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